We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders...
NEW YORK, Aug. 29 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders...
Plaintiff claims suffered damages in Korean Air Lines price fixing conspiracy SEATTLE, Aug. 10 /PRNewswire/ -- Seattle-based law firm Hagens Berman Sobol Shapiro filed a class action lawsuit...
NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases...
Company Cites Continuing Progress on Clinical and Preclinical Programs NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug...
NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company primarily focused on the development of new drugs to treat cancer and...
NEW YORK, June 25 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats...
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and...
NEW YORK, May 24 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drugs for the treatment of cancer and inflammatory diseases, announced today...
History of Atiprimod Appears in Genetic Engineering & Biotechnology News NEW YORK, May 15 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
4 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
12 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
26 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
52 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
156 | 0 | 0 | 0.14 | 0.14 | 0.14 | 0 | 0 | CS |
260 | 0.015 | 12 | 0.125 | 0.16 | 0.08 | 1648 | 0.12148515 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions